|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Src inhibition derepressed PPARγ transcriptional activity leading to induced expression of lipolytic gene fatty acid binding protein (FABP) 4 which accompanies reduced lipid droplets and decreased tumor growth.
|
30755372 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results showed that tumor grade and recurrence had a significant correlation with the expression of FABP4 (P = 0.002 and 0.049, respectively).
|
30694572 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors with high and low FABP4 and FABP6 expression have no significant correlation in tumor size, tumor site, distant organ and lymph node metastasis, histologic grade, lymphatic permeation, neurological invasion, vascular invasion, and Duke's and TNM classification.
|
31651326 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Glioblastoma cells exhibited a higher level of FABP4 expression than control cells, and down-regulation of FABP4 suppressed tumor cell growth and metastasis in vitro and in vivo.
|
30536325 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, overexpression of FABP4 led to inhibit tumor growth and decreased tumor volume in vivo.
|
29733540 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In summary, we showed that eFABP4 plays a key role in tumor proliferation and activates the expression of fatty acid transport proteins in MCF-7 breast cancer cells.
|
27061264 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mechanistic investigations showed that FABP4 upregulation increased IL-6 expression and signal transducer and activator of transcription factor 3 phosphorylation leading to DNMT1 overexpression and further silencing of the p15<sup>INK4B</sup> tumor-suppressor gene in AML cells.
|
27885273 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo, we found that increased NOTCH1 signalling in tumour xenografts led to increased expression of endothelial FABP4 that decreased when NOTCH1 and VEGFA inhibitors were used in combination.
|
27568980 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of PLIN1 (p < 0.001), FABP4 (p = 0.029), CPT-1A (p = 0.001), ACOX-1 (p < 0.001), and FASN (p < 0.001) differed significantly among these tumor subtypes.
|
25751270 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining revealed that FABP4 expression in the tumor tissue was much higher than that in the non-tumor area of the same specimen.
|
24425381 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms.
|
24240026 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Progression-associated gene profiles could be defined (e.g., FABP4 and CTSE) and were already present in the preceding noninvasive papillary tumors.
|
15958626 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In experimental systems AP-2 factors possess tumor suppressor-like activities, and alterations in the AP-2 expression pattern have been described for some tumor entities.
|
11485026 |
2001 |